p2Ca

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物,专注于信号通路和疾病研究领域。
p2Ca 

p2Ca是8聚体肽,是天然加工并呈递给Ld同种异体T细胞克隆2C的配体。

p2Ca

p2Ca Chemical Structure

CAS No. : 142606-55-1

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

p2Ca 相关产品

同靶点产品:

同靶点蛋白产品:

生物活性

p2Ca, an 8-mer peptide, is a ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C.

体外研究
(In Vitro)

p2Ca and QL9 peptides assume distinct conformations when bind to Ld and, furthermore, demonstrate that there is flexibility in peptide binding within the MHC class I cleft. Ld antigenic peptide p2Ca (LSPFPFDL) is 8-mer that lack the proline at position 2 and thus use alternative amino-terminal anchors. The p2Ca octamer is identified as the ligand that is naturally processed and presented to the Ld-alloreactive T cell clone, 2C[1]. p2Ca, is immunodominant in allorecognition of the murine MHC class I molecule H-2Ld. The majority of Ld-alloreactive T-cell clones are specific for Ld-p2Ca and this immunodominance is not due to peptide cross-reactivity[2]. p2Ca is a ubiquitously expressed self-peptide. p2Ca is derived from the mouse mitochondrial enzyme α-ketoglutarate dehydrogenase. p2Ca is present in every tissue of BALB/c mice that has been examined, including the spleen and thymus. It is also expressed by mouse tumor cell lines such as the mastocytoma P815. CTL derived in vitro recognize specifically the p2Ca/L d complex and use Vβ8 regions predominantly. The cultured cells lyse target cells with lower levels of p2Ca than the levels used for induction. This result suggests that it may be possible to use peptides at high concentrations to elicit CTL that react with endogenous levels of a peptide/class I complex[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

p2Ca 相关抗体:

体内研究
(In Vivo)

BALB/c mice, coinjected with a syngeneic BALB/c myeloma and exogenous p2Ca, are able to reject the tumor. The p2Ca/L d system may thus provide a model for evaluating the parameters for effective immunotherapy with tumor-associated peptides[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

935.07

Formula

C47H66N8O12

CAS 号

142606-55-1

Sequence

Leu-Ser-Pro-Phe-Pro-Phe-Asp-Leu

Sequence Shortening

LSPFPFDL

结构分类
  • Others
初始来源
  • 动物

tissues of H-2d mice

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
纯度 & 产品资料
Data Sheet (519 KB) 产品使用指南 (1538 KB)

参考文献
  • [1]. Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14.  [Content Brief]

    [2]. Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6.  [Content Brief]

    [3]. Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8.  [Content Brief]

Animal Administration
[3]

Mice: The effectiveness of self-peptide treatment is evaluated using a syngeneic system with the BALB/c derived myeloma Sp2/0. B2 [an Ld transfectant of Sp2/0 (19)] is incubated for the indicated times with 3 or 30 μM p2Ca or without p2Ca. A binding assay with 125I-labeled anti-Ld antibody 28-14-8 is performed[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Hornell TM, et al. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14.  [Content Brief]

    [2]. Connolly JM, et al. The peptide p2Ca is immunodominant in allorecognition of Ld by beta chain variable region V beta 8+ but not V beta 8- strains. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11482-6.  [Content Brief]

    [3]. Tjoa BA, et al. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection. Cancer Res. 1994 Jan 1;54(1):204-8.  [Content Brief]

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务